These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15752743)

  • 1. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles.
    Douaisi M; Dussart S; Courcoul M; Bessou G; Lerner EC; Decroly E; Vigne R
    Biochem Biophys Res Commun; 2005 Apr; 329(3):917-24. PubMed ID: 15752743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein.
    Hassaïne G; Courcoul M; Bessou G; Barthalay Y; Picard C; Olive D; Collette Y; Vigne R; Decroly E
    J Biol Chem; 2001 May; 276(20):16885-93. PubMed ID: 11278465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
    J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    Liu B; Yu X; Luo K; Yu Y; Yu XF
    J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
    Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
    J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more?
    Carr JM; Davis AJ; Feng F; Burrell CJ; Li P
    Curr Drug Targets; 2006 Dec; 7(12):1583-93. PubMed ID: 17168833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
    Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV: a tough viral nut to crack.
    Pomerantz RJ
    Nature; 2002 Aug; 418(6898):594-5. PubMed ID: 12167840
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Marin M; Rose KM; Kozak SL; Kabat D
    Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The viral infectivity factor (Vif) of HIV-1 unveiled.
    Rose KM; Marin M; Kozak SL; Kabat D
    Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Yu X; Yu Y; Liu B; Luo K; Kong W; Mao P; Yu XF
    Science; 2003 Nov; 302(5647):1056-60. PubMed ID: 14564014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
    Schäfer A; Bogerd HP; Cullen BR
    Virology; 2004 Oct; 328(2):163-8. PubMed ID: 15464836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
    Kao S; Miyagi E; Khan MA; Takeuchi H; Opi S; Goila-Gaur R; Strebel K
    Retrovirology; 2004 Sep; 1():27. PubMed ID: 15373943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Conticello SG; Harris RS; Neuberger MS
    Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.